This is a working overview of counterion, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-14. Anything still debated is marked as such rather than presented as settled.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.
| Property | Value | Notes |
|---|---|---|
| Typical purity | 95% or higher | By reversed-phase HPLC area |
| Identity method | Electrospray mass spectrometry | Confirms molecular mass |
| Purity method | Reversed-phase HPLC | Detection near 214 nm |
| Primary degradation | Methionine oxidation | Sulfoxide product, +16 Da |
| Solution storage | 2-8 °C, short term | Aliquot to avoid freeze-thaw |
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Semax is supplied as a lyophilized powder that appears white to off-white. It dissolves readily in water, phosphate-buffered saline, and other aqueous media, which simplifies preparation of working solutions for laboratory use. The nasal products registered in Russia are dilute aqueous solutions, typically around 0.1 percent peptide by weight. Organic solvents are rarely necessary and can complicate handling. Because the peptide is hygroscopic, weighing should be performed quickly and with minimal exposure to ambient humidity.
Solid material is normally kept at minus 20 degrees Celsius in a sealed, desiccated container. Reconstituted solutions are less stable and are usually divided into single-use aliquots before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of activity. Light exposure is minimized by using amber glassware or foil wrapping. Published stability data for this peptide are sparse, so recommended storage conditions rest mainly on general practice for short synthetic peptides rather than on dedicated study.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.
{\displaystyle {\begin{aligned}z:\ &\rho \left({\partial _{t}u_{z}}+u_{x}{\partial _{x}u_{z}}+u_{y}{\partial _{y}u_{z}}+u_{z}{\partial _{z}u_{z}}\right)\\&\quad =-{\partial _{z}p}+\mu \left({\partial _{x}^{2}u_{z}}+{\partial _{y}^{2}u_{z}}+{\partial _{z}^{2}u_{z}}\right)+{\frac {1}{3}}\mu \ \partial _{z}\left({\partial _{x}u_{x}}+{\partial _{y}u_{y}}+{\partial _{z}u_{z}}\right)+\rho g_{z}.\end{aligned}}}
Soon after, Russian state media officially reported that Assad had fled to Moscow. He was subsequently "personally granted asylum" by Russian president Vladimir Putin. The spokesperson refused to comment on the specific whereabouts of Assad, saying that Putin was not planning to meet him.
Multicellularity was made possible by the development of the extracellular matrix (ECM) similar in function to the bacterial EPS that consists of extracellular polymeric substances. EPS enables microbial cell adhesion, and is believed to be the first evolutionary step toward multicellular organisms. Basement membranes are a type of specialized extracellular matrix that surrounds most animal tissues, and are essential in their formation. Extracellular matrix components of laminin domains, integrated with other proteins such as cadherins have been described in single-celled motile choanoflagellates that pre-dates the evolutionary emergence of basement membranes, one of the two types of ECM. The emergence of the basement membrane coincided with the origin of multicellularity. The other type of ECM is the interstial matrix. The evolution of multicellularity from unicellular ancestors has been replicated in the laboratory, in evolution experiments using predation as the selective pressure.
J. Lyons & Co. was a British restaurant chain store, food manufacturing, and hotel conglomerate founded in 1884 by Joseph Lyons and his brothers in law, Isidore and Montague Gluckstein. Lyons' first teashop opened in Piccadilly, London in 1894, and from 1909 they developed into a chain of teashops, with the firm becoming a staple of the High Street in the UK. At its peak the chain numbered around 200 cafes. The teashops provided for tea and coffee, with food choices consisting of hot dishes and sweets, cold dishes and sweets, and buns, cakes and rolls. Making their first cakes and pastries in 1894, several Lyons cake products are still available on grocers' shelves, including Lyons' treacle tart, Lyons' Bakewell tart, Lyons' Battenberg, and Lyons' trifle sponges, which are sold by Premier Foods. The company is also known for its pioneering use of computers in the office.
Despite these conclusions, all researchers observed a degree of managerial activities among the groups they studied. All observed networks and a degree of persistence, and there may be utility in focusing on the identification of organizing roles of people and events rather than the group's structure. There may be three main approaches to understand the organizations in terms of their roles as social systems:
Sources: en.wikipedia.org
=== Microscopy === Microscopy of the skin sample obtained from the biopsy is used to detect the presence of cleavage within the dermis, epidermal acantholysis (breaking apart of the skin), dyskeratotic keratinocytes and vacuolar changes in the layers of the skin, interfacial dermatitis, and epidermal exocytosis. Presentation of these characteristics suggests PNP.
==== Grain ==== Grain, which includes dry kitchen ingredients such as flour, rice, millet, couscous, cornmeal, and so on, must be stored correctly to prevent insect or rodent infestation. Metal cans are used (in the United States, the smallest practical grain storage uses closed-top #10 metal cans measuring about 3 to 3.5 liters). Storage in grain sacks is ineffective; mold and pests can destroy a 25 kg cloth sack of grain within a year, even when stored off the ground in a dry area. On the ground or damp concrete, grain can spoil in as little as three days, and the grain might have to be dried before it can be milled. Food stored under unsuitable conditions should not be purchased or used because of the risk of spoilage. To test whether the grain is still good, sprout it. If it sprouts, it is still good, but if not, it should not be eaten.
== Industrial uses == Micrococci, like many other representatives of the Actinobacteria, can be catabolically versatile, with the ability to utilize a wide range of unusual substrates, such as pyridine, herbicides, chlorinated biphenyls, and oil. They are likely involved in detoxification or biodegradation of many other environmental pollutants. Other Micrococcus isolates produce various useful products, such as long-chain (C21-C34) aliphatic hydrocarbons for lubricating oils.
=== Sandia National Laboratories and implantable insulin pump development === In parallel with early academic and commercial efforts, significant development of implantable insulin delivery systems was carried out at Sandia National Laboratories in collaboration with the University of New Mexico School of Medicine during the late 1970s and early 1980s. This work focused on the design of an electronically controlled, remotely programmable insulin infusion system intended to more closely replicate the physiological function of the human pancreas. The Sandia–UNM system built upon earlier external insulin pumps and incorporated engineering approaches derived from high-reliability systems, including precise flow control and programmable delivery rates. The implantable device was tested in animal models and subsequently implanted in human patients beginning in January 1981, with additional implantations reported in early 1982. Key engineering contributions to the system were made by a multidisciplinary team at Sandia, including Gary A. Carlson, Raymond E. Bair, John I. Gaona Jr., Jerry T. Love, and Ruben S. Urenda, who co-authored foundational technical reports describing the design and operation of the implantable, remotely programmable insulin infusion system. Earlier engineering work on insulin delivery systems by members of the Sandia–UNM collaboration was also described in peer-reviewed literature, including analysis of system design considerations such as flow control, programmability, and reliability.
Both testosterone and 5α-DHT are metabolized mainly in the liver. Approximately 50% of testosterone is metabolized via conjugation into testosterone glucuronide and to a lesser extent testosterone sulfate by glucuronosyltransferases and sulfotransferases, respectively. An additional 40% of testosterone is metabolized in equal proportions into the 17-ketosteroids androsterone and etiocholanolone via the combined actions of 5α- and 5β-reductases, 3α-hydroxysteroid dehydrogenase, and 17β-HSD, in that order. Androsterone and etiocholanolone are then glucuronidated and to a lesser extent sulfated similarly to testosterone. The conjugates of testosterone and its hepatic metabolites are released from the liver into circulation and excreted in the urine and bile. Only a small fraction (2%) of testosterone is excreted unchanged in the urine. In the hepatic 17-ketosteroid pathway of testosterone metabolism, testosterone is converted in the liver by 5α-reductase and 5β-reductase into 5α-DHT and the inactive 5β-DHT, respectively. Then, 5α-DHT and 5β-DHT are converted by 3α-HSD into 3α-androstanediol and 3α-etiocholanediol, respectively. Subsequently, 3α-androstanediol and 3α-etiocholanediol are converted by 17β-HSD into androsterone and etiocholanolone, which is followed by their conjugation and excretion. 3β-Androstanediol and 3β-etiocholanediol can also be formed in this pathway when 5α-DHT and 5β-DHT are acted upon by 3β-HSD instead of 3α-HSD, respectively, and they can then be transformed into epiandrosterone and epietiocholanolone, respectively.
Sources: en.wikipedia.org
Dry powder is normally held at -20 °C or lower, away from light and moisture. Sealed vials can also be kept at 2-8 °C for shorter intervals. Warming to room temperature before opening prevents condensation.
In solution, hydrolysis of peptide bonds and oxidation of the methionine residue are the principal concerns. Oxidation converts methionine to its sulfoxide form, shifting the mass by sixteen daltons. Both processes are slowed by cold storage and by avoiding alkaline conditions.
A certificate documents what the supplier measured on a specific lot, not how a laboratory will use the material. Independent verification of identity and purity is common practice. Acceptance criteria should be defined before a batch is ordered.
It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.